Title story in the journal Cancers highlights discovery by Kancera scientists
Kancera AB (Nasdaq First North Premier Growth Market: KAN) has previously announced groundbreaking research results for Kancera’s fractalkine blockers, which could pave the way for new treatments of ovarian cancer. The journal Cancers (https://www.mdpi.com/journal/cancers) has chosen to top their website with this discovery.
The research results have been generated in a research collaboration with Nina Gustafsson’s research group at Karolinska Institutet and Scilifelab, where Kancera’s PhD students Jemina Lehto and Anna Huguet are the first authors of the article “Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum (1). The research has taken place within the framework of the EU project SYNTRAIN (2).
(1) Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum. https://www.mdpi.com/2072-6694/13/6/1442
(2) This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 722729.Back